These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11118904)

  • 21. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.
    Lee YN; Suk Hwang H; Kim MC; Lee YT; Cho MK; Kwon YM; Seok Lee J; Plemper RK; Kang SM
    Virology; 2015 Feb; 476():217-225. PubMed ID: 25553517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsiveness.
    Miller M; Cho JY; Baek KJ; Castaneda D; Nayar J; Rodriguez M; Roman M; Raz E; Broide DH
    Vaccine; 2002 Jul; 20(23-24):3023-33. PubMed ID: 12126916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
    Goetsch L; Plotnicky-Gilquin H; Champion T; Beck A; Corvaïa N; Stâhl S; Bonnefoy JY; Nguyen TN; Power UF
    Vaccine; 2000 Jun; 18(24):2735-42. PubMed ID: 10781861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung.
    Tree JA; Bembridge G; Hou S; Taylor G; Fashola-Stone E; Melero J; Cranage MP
    Vaccine; 2004 Jun; 22(19):2438-43. PubMed ID: 15193407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium.
    Xie C; He JS; Zhang M; Xue SL; Wu Q; Ding XD; Song W; Yuan Y; Li DL; Zheng XX; Lu YY; Shang Z
    Hum Gene Ther; 2007 Aug; 18(8):746-52. PubMed ID: 17696764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS
    Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture.
    Shao HY; Hsu HS; Yu SL; Wu SR; Hu KC; Chang CK; Liu CC; Chow YH
    Antiviral Res; 2016 Jun; 130():27-35. PubMed ID: 27001351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.
    Martinez X; Li X; Kovarik J; Klein M; Lambert PH; Siegrist CA
    Eur J Immunol; 1999 Oct; 29(10):3390-400. PubMed ID: 10540351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.